STOCK TITAN

BriaCell Therapeutics Corp - BCTXW STOCK NEWS

Welcome to our dedicated news page for BriaCell Therapeutics (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BriaCell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BriaCell Therapeutics's position in the market.

Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is presenting findings at the 2023 San Antonio Breast Cancer Symposium, demonstrating the effectiveness of their Bria-IMT™ combination regimen in activating cancer-fighting T cells and producing unique antibody responses in patients with disease control. Advanced CD8 ImmunoPET imaging showed the transformation of cold immune suppressed tumors to hot immune responsive ones, indicating the potential of the treatment in cancer patients. The company also plans to present updated overall survival clinical data, showing significant anti-tumor activity of Bria-IMT™ in advanced metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announces a remarkable responder in their Phase 2 study of the Bria-IMT™ combination regimen. A patient with extensive metastatic breast cancer behind the eye experienced a remarkable improvement of eye-bulging 'proptosis' and significant pain reduction after only 3 cycles of treatment. The patient had previously failed 7 regimens and continues to receive treatment. Additional survival updates and clinical data sets will be presented at the San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
none
-
Rhea-AI Summary
BriaCell reports unprecedented immune system activation in tumor models with its next generation breast and prostate cancer immunotherapies. The FDA has authorized BriaCell's Investigational New Drug Application (IND) for Bria-OTS™, opening the path to clinical trials. The company's immunotherapies have shown enhanced efficacy and safety profiles, with potential advantages including precision therapy, favorable safety profiles, rapid and cost-effective treatments, and potent immune system activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.41%
Tags
none
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) and a new member to its scientific advisory board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
management
-
Rhea-AI Summary
BriaCell Therapeutics recognizes Breast Cancer Awareness Month and reports positive clinical results in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces upcoming presentations at scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
Rhea-AI Summary
BriaCell partners with NYCBS to evaluate Bria-IMT combination in Phase 3 study for advanced breast cancer patients in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
partnership clinical trial
-
Rhea-AI Summary
BriaCell's pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor has been fully approved and will enroll patients with advanced metastatic breast cancer. Positive results could lead to full approval and marketing authorization for Bria-IMT™. The study's primary endpoint is overall survival. Bria-IMT™ is currently under Fast Track Designation by the FDA. Successful completion of the study would allow BriaCell to submit a Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
Rhea-AI Summary
BriaCell reports strong patient survival benefit in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none
BriaCell Therapeutics Corp

Nasdaq:BCTXW

BCTXW Rankings

BCTXW Stock Data

11.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
West Vancouver

About BCTXW

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.